3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
5
Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Skin Neoplasms
2
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Hot Flashes
2
Vulvodynia
1
Thromboembolism
1
Severe Acute Respiratory Syndrome
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Hemorrhage
1
Pleural Effusion, Malignant
1
Platinum Resistant Ovarian Cancer
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Pain, Postoperative
1
Neutropenia
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myasthenia Gravis
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Interventions
Temozolomide
47
Bevacizumab
41
Radiotherapy
17
Magnetic Resonance Spectroscopy
14
Irinotecan
11
Nivolumab
8
Everolimus
7
Radiation
6
poly ICLC
5
X-Rays
5
Phantoms, Imaging
5
Carboplatin
5
pembrolizumab
4
fluorodopa F 18
4
Specimen Handling
4
Nuclear Medicine Department, Hospital
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Erlotinib Hydrochloride
4
Carmustine
4
ribociclib
3
palbociclib
3
ivosidenib
3
antineoplaston A10
3
Vorinostat
3
Radiotherapy, Intensity-Modulated
3
Radiosurgery
3
Modafinil
3
Lomustine
3
Biopsy
3
veliparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Glioma
×
Sodium Chloride
×
Clear all
NCT02465268
2025-01-14
ATTAC-II
University of Florida
Phase 2
Completed
175 enrolled
18 charts